Stock Price Forecast

May 28, 2020


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Akorn, Inc. chart...

About the Company

Akorn, Inc. engages in the development, manufacture, and marketing of generic and prescription pharmaceuticals, and animal and consumer health products. It operates through the Prescription Pharmaceuticals and Consumer Health business segments. The Prescription Pharmaceuticals segment manufactures and markets generic and branded prescription pharmaceuticals including ophthalmic, injectable, oral liquids, topical, inhalants, and nasal sprays. The Consumer Health segment offers branded and private-label animal health; and over-the-counter products. The company was founded in 1971 and is headquartered in Lake Forest, IL.

Sector

Health Technology

Industry

Pharmaceuticals: Major

Employees

2227

CEO

Douglas S. Boothe

Exchange

NASDAQ

Website

http://www.akorn.com

$721M

Total Revenue

2K

Employees

$23M

Market Capitalization

-0.06

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $AKRX News

Akorn Reaches New 52-Week High (AKRX)

11y ago, source: TheStreet.com

Shares are up 27.2% year to date as of the close of trading on Thursday. Akorn, Inc. engages in the manufacture and marketing of diagnostic and therapeutic ophthalmic pharmaceuticals products ...

Attorneys’ Fees for Merger Disclosures to Get Objector’s Attack

8d ago, source:

Ted Frank, a frequent objector in class actions, may participate in two largely resolved suits for additional disclosures in drugmaker Akorn Inc.'s proxy documents for a merger with Fresenius Kabi AG ...

Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up

7y ago, source: TheStreet.com

Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion, or $34 per share. Fresenius announced a deal to buy U.S. generic drugmaker Akorn Inc for $4.75 billion ...

7th Circuit Lets Shareholder Intervene in Mootness Fees Spat

8d ago, source: Law

Here, Akorn Inc. shareholders brought several lawsuits against the pharmaceutical company alleging its proxy statement asking investors to approve a merger failed to disclose information in ...

Seventh Circuit Decision Outlines Framework To Allow Courts To Evaluate Individual Mootness Fees in Merger Challenge Lawsuits

8d ago, source: JD Supra

The U.S. Court of Appeals for the Seventh Circuit in Jorge Alcarez, et al. v. Akorn Inc., et al. 1 mapped out one means by which a court may evaluate mootness fees paid to individual shareholders ...

Selling Your Business Later: 5 Must-Do's Now

4y ago, source: Forbes

And that can come back to haunt you. Recently, a large public German dialysis business, Fresenius SE, entered into a merger agreement to acquire Akorn Inc., a public generic drug maker.

Rising Estimates Show Akorn To Be Apple Of Analysts' Eyes

12y ago, source: Forbes

We track earnings estimate revisions to spot hot stocks. On August 2 Akorn reported quarterly results that were highlighted by a revenues of $32.1 million, a 59% increase over the same period last ...

Bring Your Own Execution Drugs, Arizona Tells Death-Row Lawyers

7y ago, source: Courthouse News Service

Danish pharmaceutical company Lundbeck restricted access to Nembutal, a name brand for pentobarbital, for executions after widespread public protest in 2011 and sold the rights to the drug to Illinois ...

Prestige Consumer (PBH) Banks on its Portfolio Amid Cost Woes

22d ago, source: Zacks.com on MSN

Prestige Consumer Healthcare Inc.’s PBH brand-building strategy and growing strength in the e-commerce channel are tailwinds.

Etsy Inc.

2d ago, source: Wall Street Journal

1 Day ETSY -0.46% DJIA 0.67% S&P 500 0.87% Retail/Wholesale 0.37% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the ...

Viatris Announces the Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% in the United States

23d ago, source: Morningstar

PITTSBURGH, April 1, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced the U.S. commercial launch of RYZUMVI™ (phentolamine ophthalmic solution) 0. ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...